Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius SE & Co. KGaA    FRE   DE0005785604

FRESENIUS SE & CO. KGAA

(FRE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fresenius : 4Q Net Profit Declines; Confirms Preliminary Guidance

02/23/2021 | 01:31am EST

By Cecilia Butini

Fresenius SE & Co. said Tuesday that its net profit declined slightly in the fourth quarter of 2020 on mostly flat sales, and confirmed its previously reported guidance for 2021.

The German healthcare company reported a profit of 494 million euros ($600.6 million) for the quarter before special items, down from EUR506 million the previous year, it said. Sales came in flat at EUR9.3 billion, Fresenius said.

The figures are within company guidance, Fresenius said, as it had previously reported in a preliminary statement.

For 2021, the company expects a hit from the coronavirus pandemic as previously reported in preliminary statements. It sees sales growth in the low to mid-single digit percentage range and broadly stable net income on year, it said.

Fresenius Medical Care, the company's dialysis division, reported net income of EUR372 million excluding special items in the fourth quarter, slightly up from EUR368 million the previous year, the company said. This meant Fresenius Medical Care achieved its 2020 targets as previously announced in preliminary results.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

02-23-21 0131ET

Stocks mentioned in the article
ChangeLast1st jan.
FRESENIUS MEDICAL CARE AG & CO. KGAA 0.76% 58.62 Delayed Quote.-14.69%
FRESENIUS SE & CO. KGAA 0.19% 36.02 Delayed Quote.-5.05%
All news about FRESENIUS SE & CO. KGAA
03/01DGAP-DD  : Fresenius Medical Care AG & Co. KGaA english
DJ
03/01FMC FRESENIUS MEDICAL CARE AG & CO K : Buy rating from Berenberg
MD
02/26PRESS RELEASE  : Nanogate SE: Divestment of Nanogate Kierspe GmbH
DJ
02/26FMC FRESENIUS MEDICAL CARE AG & CO K : Buy rating from Goldman Sachs
MD
02/26FMC FRESENIUS MEDICAL CARE AG & CO K : Gets a Neutral rating from JP Morgan
MD
02/26FRESENIUS SE  : JP Morgan gives a Buy rating
MD
02/25FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
02/25FMC FRESENIUS MEDICAL CARE AG & CO K : Independant Research reiterates its Buy r..
MD
02/25DGAP-DD  : Fresenius SE & Co. KGaA english
DJ
02/25DGAP-DD  : Fresenius Medical Care AG & Co. KGaA english
DJ
More news
Financials
Sales 2020 36 158 M 43 409 M 43 409 M
Net income 2020 1 735 M 2 083 M 2 083 M
Net Debt 2020 23 519 M 28 236 M 28 236 M
P/E ratio 2020 11,4x
Yield 2020 2,24%
Capitalization 20 030 M 24 153 M 24 047 M
EV / Sales 2020 1,20x
EV / Sales 2021 1,13x
Nbr of Employees 309 114
Free-Float 72,0%
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 45,55 €
Last Close Price 35,93 €
Spread / Highest target 89,3%
Spread / Average Target 26,8%
Spread / Lowest Target -50,8%
EPS Revisions
Managers and Directors
NameTitle
Stephan Sturm President & Chief Executive Officer
Rachel Clare Empey Chief Financial Officer
Gerd Krick Chairman-Supervisory Board
Jürgen Götz Chief Legal & Compliance Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Sector and Competitors